US FDA's Record-Breaking Month Of Breakthrough Therapy Designations
Executive Summary
Alnylam's ALN-AS1 became the eighth announced therapy to receive a breakthrough designation in May 2017, breaking the previously monthly high of seven.
You may also be interested in...
Breakthrough Therapy Designations Set Quarterly Record
US FDA granted designations for several products based on late-stage data; with at least 19 breakthrough therapy designations, five-year-old program sets another record in first quarter of 2018.
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris
The latest drug development news and highlights from our US FDA Performance Tracker.
Breakthrough Requests Keep Climbing
Sponsors are seeking US “Breakthrough Therapy” Designations at a record pace in FY 2017.